Recent advances in genetics, brain imaging, and molecular analyses of postmortem tissue have helped generate a considerable body of information related to the etiology and pathophysiology of schizophrenia. But ''information is not knowledge,'' and with this accumulating information we have come to appreciate the enormous complexity of genetic and nongenetic causes of schizophrenia. This has, invariably, led to reduced optimism that we will discover treatments that cure schizophrenia or even provide better efficacy than current antipsychotic medications. We also are beginning to appreciate that, similar to other brain disorders such as Parkinson's or Alzheimer's disease, by the time schizophrenia presents itself at a behavioral level, the neuronal damage may be irreversible. Given this, one of our best chances for improving the outcome of this illness is to prevent its progression. In the last decade, based on the work of McGorry and Yung at University of Melbourne and McGlashan and Miller at Yale, the clinical field of schizophrenia has advanced toward identifying individuals at the socalled prodromal phase of the illness, who are at high risk for psychosis (Cannon et al., 2008) . A critical implication of this effort is that, by identifying and following the clinical outcome of these individuals, we may be able to identify risk factors for psychosis (Addington and Heinssen, 2012; Kaur and Cadenhead, 2010) . This can be done both by using multimodal noninvasive methods in at-risk individuals to characterize changes in brain events that occur before or during transition to psychosis, as well as applying relevant animal models to reveal potential biological mechanisms underlying these changes. It is hoped that this mechanistic knowledge will, in turn, allow us to develop safe and effective interventions to prevent the emergence of psychosis in these individuals.
The paper published in this issue of Neuron (Schobel et al., 2013) represents the new wave of translational studies focused on the strategy of detection and intervention for schizophrenia. The longitudinal design of this study identified a spatiotemporally concordant pattern of hippocampal hypermetabolism and atrophy during the emergence of psychosis in at-risk individuals. Using an animal model that produced a similar pattern of hippocampal disruption, the authors identified a potential mechanism-enhanced glutamate availability-that may drive the psychosis-associated progression from hypermetabolism to atrophy. Given these data, interventions that attenuate glutamate availability may mitigate psychosis in individuals at-risk for schizophrenia.
The clinical results by Schobel et al. (2013) may also provide mechanistic insight on recent work that links elevated striatal dopamine availability to prodromal signs of schizophrenia and to probability of transition to psychosis (Egerton et al., 2013) . There have been reports of an aberrant relationship between hippocampal glutamate levels and striatal dopamine availability in individuals at high risk to develop schizophrenia (Stone et al., 2010) . Thus, the findings by Schobel et al. (2013) suggest that enhanced hippocampal glutamate, in addition to causing relatively localized atrophy, may also drive the dopamine abnormalities that accompany the transition to psychosis.
Animal models and human postmortem studies (Longson et al., 1996) have long implicated excess glutamate in cortical and hippocampal regions in the pathophysiology of schizophrenia. Although the idea of hyperfunctionality of glutamate synapses is counterintuitive to some traditional views on glutamate neurotransmission and schizophrenia, the mechanism has gained acceptance because it is consistent with a number of clinical findings. At a theoretical level, this hyperfunctionality may serve as a common pathway for the diverse genetic causes of the illness (Moghaddam, 2003) and is consistent with neurotoxic processes including apoptosis that may mediate cortical and hippocampal atrophy (Glantz et al., 2006) . At a mechanistic level, excess glutamate availability may help explain other pathophysiological findings in schizophrenia such as an adaptive change in GABA interneuron function reported in postmortem tissue (Schobel et al., 2013) , and imaging findings of enhanced dopamine neurotransmission (Howes et al., 2012) , given that dopamine neurons receive glutamate projections from hippocampus and prefrontal cortex. Based, in part, on these previous findings, reducing glutamate neurotransmission in schizophrenia through a modulatory mechanism such as agonism of metabotropic glutamate receptor 2 (mGlu2) has been in the conceptual pipeline for more than a decade. While the approach of reducing glutamate availability may not provide long-term efficacy for treating psychosis in chronically ill patients (Kinon and Gó mez, 2013) , the study by Schobel et al. (2013) suggests it may be a useful approach as a prevention strategy in individuals at high risk for schizophrenia.
The finding that excess glutamate may be a pathogenic driver in at-risk individuals may also provide a mechanism for why first psychotic episodes in schizophrenia often are manifested in response to stress (Kaur and Cadenhead, 2010) . Extracellular levels of glutamate in hippocampus and prefrontal cortex are exquisitely sensitive to stress. Under normal conditions, the stress-induced increase in glutamate efflux is cleared from the extracellular space within minutes (Bagley and Moghaddam, 1997) . However, if genetic predisposition to schizophrenia imparts an elevated tone of glutamate neurotransmission by increasing extracellular glutamate availability (Figure 1 ), exposure to stress and the resulting increase in glutamate can push the system beyond a certain threshold that then leads to atrophy. The glutamatergic link with stress also suggests that nonpharmacologic approaches should be taken seriously as intervention strategies. Although cognitive remediation trials are ongoing in early stages of the illness (Addington and Heinssen, 2012), a more comprehensive approach aimed at reducing stress reactivity and anxiety may be more effective at this stage.
Excess glutamate may also lead to oxidative stress and neuroinflammation during the prodromal stage (Kaur and Cadenhead, 2010) . It is interesting that treatments that target inflammation and related mechanisms, such as dietary omega-3 fatty acids, appear to be effective in reducing transition to psychosis in at-risk individuals (Amminger et al., 2010) despite having inconsistent or no therapeutic efficacy in chronic patients. On the other hand, treatments with common antipsychotic drugs do not seem to be effective for preventing transition to psychosis in at-risk individuals (Kaur and Cadenhead, 2010) . Insofar as ketamineinduced glutamate release models some aspects of the prodromal hippocampal hypermetabolism (Schobel et al., 2013) , this lack of efficacy is not unexpected. In similar animal models, antipsychotic drugs, including clozapine, are not effective in reversing enhanced glutamate release (Adams and Moghaddam, 2001 ).
These drugs, in fact, can increase resting extracellular levels of glutamate (Daly and Moghaddam, 1993) . Clearly, their use in chronically ill patients may not adversely affect glutamate release, but given that the work by Schobel et al. (2013) makes a strong case for excess glutamate to be a pathogenic driver, use of antipsychotic drugs may hasten the transition to psychosis and, therefore, should be avoided during the prodromal stage of the illness.
Prevention strategies are now commonplace in most fields of medicine. This includes neurology, where dietary and other lifestyle recommendations have become mainstream for prevention or reduction of illness progression for brain disorders such as Alzheimer's disease. Early identification of individuals who are at high risk to develop schizophrenia holds the promise of advancing preventive treatment to psychiatry, and in particular to prevention of schizophrenia. Research so far indicates that pathophysiological changes in the prodrome and first-episode patients may be distinct from that observed in chronic As demonstrated in the figure, this can involve a diverse group of proteins in different patients that form functional clusters (green) of glutamate-influencing proteins. These clusters can influence a wide range of metabolic or degradation pathways for glutamine and glutamate, or the function of the glutamate synapse through receptor, transporters, or signal transduction mechanisms.
(D) A consequence of this clustering is enhanced glutamate availability in affected regions, resulting in hypermetabolism as described by Schobel et al. (2013) . This hyperglutamatetgic (and hypermetabolic) state might only cause transient effects in at-risk individuals that are expressed as increased anxiety or cortical noise that may produce cognitive deficits. Insults such as stress, which cause further glutamate release in vulnerable regions such as the hippocampus, may push these levels beyond a threshold that can be cleared from the extracellular milieu. This excess glutamate may lead to spreading hypermetabolism and irreversible atrophy.
patients (Kaur and Cadenhead, 2010) and that early intervention with traditional antipsychotic drugs may not only be ineffective, but may actually worsen the outcome. This makes longitudinal and mechanistically oriented translational approaches such as that applied by Schobel et al. (2013) especially critical for the design of prevention strategies to prevent psychosis in individuals at high clinical risk for schizophrenia.
It has been known for decades that a fraction of neuronal tubulin is insoluble in cold and also resistant to calcium as well as drugs that depolymerize microtubules. In this issue of Neuron, Song et al. (2013) suggest that this unusual stability results from the polyamination of tubulin by transglutaminase.
For years, it was routine that each new generation of microtubule researchers would learn to make tubulin preps from bovine or porcine brain (Miller and Wilson, 2010) . This would involve regular trips to a slaughterhouse, waiting for the brains to become available so that they could immediately be put on ice and rushed back to the lab, minced, and then put into a blender with cold buffer. From there, the strategy was based on the simple principle that microtubules would disassemble into soluble tubulin in the cold and reassemble into microtubules when the prep was warmed. Through cycles of warming and cooling, the prep would become progressively more enriched for tubulin. For most microtubule labs, those days are gone, because molecular approaches can now accomplish what used to require this tedious procedure. Reminiscing about those earlier days brings to mind a fundamental issue about tubulin and microtubules. The initial huge pellet produced by spinning down the brain homogenate was normally washed down the drain without further consideration-but this pellet actually contained a significant amount of tubulin that was not soluble in the cold. Although this was long known, the cold-stable tubulin fraction was given little attention by most investigators-one notable exception being Scott Brady.
Nearly three decades ago, Brady et al. (1984) compared the biochemical properties of tubulin in the cold-stable fraction with the properties of the temperaturecycled tubulin. Much of the tubulin in the cold-stable fraction was shown to be extremely basic in charge, as assessed by two-dimensional electrophoresis. Not only was this different from the cycling tubulin, but, for the ensuing decades, no tubulin isoform produced by any tubulin gene or posttranslational modification became apparent that could explain this behavior.
From biochemical studies alone, it was impossible to know if the cold-insoluble tubulin represented a physiological
